Billions빌리언스

Billions is loss-making on a trailing basis, with its share price down about 71% over the past year and a sharp fall in recent months.

Billions makes hygienic and medical rubber products, mainly condoms and gloves, and also runs an entertainment business that produces dramas and manages artists. Trailing twelve-month revenue to H1 2026 is about ₩26.3B, but the company posted a net loss of about ₩20.5B, and its share price closed at ₩2,890 on 2026-10-26 with a market value of about ₩19.2B. The data does not include analyst ratings or forecasts.

What stands out

• Trailing revenue of about ₩26.3B is roughly flat against 2025's ₩22.6B, but the operating result is close to break-even at about -₩0.2B and the net loss is about -₩20.5B.
• The 2025 annual result was a net loss of about ₩6.9B, after a profit of about ₩1.7B in 2024, so the swing between years is large.
• Cash of about ₩24.3B exceeds borrowings of about ₩12.2B, and trailing free cash flow is slightly positive at about ₩0.4B.
• Price-to-book is about 0.4 and the dividend yield is 0%, while the company has no positive trailing earnings to produce a P/E.
• Recent filings include a half-year report, a derivatives trading loss notice, a trading halt, a change of CEO, and several shareholders' meeting notices, with the latest amended notice dated 2026-10-22.

What to watch

• Upcoming shareholders' meeting, including the amended notices, and any agenda items on the filings.
• Further disclosure on the derivatives trading loss and the cause of the large trailing net loss, which the data does not explain in detail.
• Whether the share price stays well below the DCF base value of ₩3,192 and the 52-week range, given the sharp drop over the past year; the DCF figure is a model output, not a forecast.